
Final Data from Teva’s PEARL Real-World Study Reinforce the Long-term Effectiveness of AJOVY® (fremanezumab) for the Prevention of Chronic and Episodic Migraine

THEON secures c.€50 million new orders, directing revenue guidance to the upper range (€430 million)
